About Us

Project Team

Kristell Lebozec, R&D Project Manager

photo-kristell-carree-180x180Master of Biotechnology Engineering with a focus on R&D and Health. K. Lebozec has a 2 years experience in academic laboratories (Institut Gustave Roussy and Centre de Recherche des Cordeliers) and in the industry (DNA Therapeutics and I-Stem). She is in charge of selecting ACT017 expression system, designing analytical methods and of the functional characterization of products.

Laurie Jullien – Regulatory Affairs and Quality

ljullienPharmD., Master of International Development and Registration of Drugs. Laurie Jullien started at Genentech (USA) in Product Drug Development and was appointed Regulatory Affairs Labelling Manager at Roche (UK). She is in charge of the regulatory and quality strategy for the development of ACT017, the IMPD dossier and the clinical trial authorisation requests for phase 1 and 2.

 

Jean-Pierre Lehner – Cardiologist and Internal Medicine, Medical Affairs Consultant

jplenherMD., cardiologist and internal medicine graduate, Jean-Pierre Lehner served during 30 years the pharmaceutical industry. Appointed Senior Vice President & Chief Medical Officer at Sanofi in 2009, Jean-Pierre Lehner had responsibility for the worldwide medical affairs, regulatory affairs, safety and HEOR research including comparative effectiveness. Before joining pharmaceutical industry, he was head of the Intensive Care Unit of Cardiology in Hospital Bichat, Paris (France). He is now Executive Director of his own company (JPLPHARMA CONSULTING).

Frédéric Pailloux – Drug Development & Regulatory Science Consultant

fpaillouxPharm.D and M.Sc. in Drug and Health Law, Senior Director at Voisin Consulting, Frederic is a Regulatory Science professional with 20+  years’ experience in the Pharmaceutical and Biotech industry. As Consultant, Frederic is actively involved in the design, preparation and management of registration applications, agency meetings and scientific advice procedures. Frederic provides support to Acticor Biotech for the development of regulatory strategies.

Olivier Loget – Non-clinical Development Consultant

ologetDVM ERT, Eurotox registered toxicologist, CapEval Pharma CEO, Olivier Loget has worked more than 28 years in toxicology departments. Olivier was appointed Head of Non-Clinical Drug Safety Department at Addex in 2006 to participate in the IPO and to create, develop and lead this department until 2010, when he created CapEval Pharma and became cofounder and CSO of OriBase Pharma. Author or co-author of more than 20 publications, he is also cofounder of the European Society of Laboratory Animal Veterinarians and President of the International Society of Ocular Toxicology.







Exports pages

Nothing to display, yet.







About Us

Board of directors

Gilles Avenard, MD – CEO & Chairman of the Board

Board member or advisor for several biotech companies ; co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. Gilles Avenard was involved in the development of several innovative medicines until their registration in Europe and the USA. Before that, he was Projects Director for Hoechst Marion Roussel (Sanofi) and Medical Director of Bio-Transfusion (LFB).

Philippe Billiald, PharmD, PhD – Censor

Professor at Paris-Sud University ; Antibody Scientific Consultant and President of the Strategic Comity. Expert in the field of therapeutic and diagnostic antibody engineering, Philippe Billiald is the author of two patents and close to 40 papers in peer-reviewed scientific journals, books and scientific magazines.

Catherine Boule – CapDecisif Management

Partner at CapDecisif Management, Catherine Boule holds a Master of Science in Molecular Biology from the University Paris VI and a degree in “Management of Technological Innovation in Bio-Industries ” from the INA Paris-Grignon / Reims Management School. She worked at the Curie Institute (CNRS) in Paris before working with innovative biotechnology start-ups for an incubator in the Paris region.

Jean Pierre Cazenave, MD – Director

Honorary Professor of Hematology and Transfusion (University of Strasbourg), President of ARMESA, a Strasbourg medical research Association and member of the French Académie Nationale de Médecine. After his MD degree (1970, University of Strasbourg), he moved to Canada at Mac Master University, Ontario, where he worked on platelet physiology and pharmacology for a PhD and was appointed Assistant Professor of Pathology. Back to Strasbourg Blood Transfusion Center (1978) to create an INSERM research unit (U311) in 1986 devoted to the Biology and Pharmacology of Hemostasis and Thrombosis. From 1987 to 2013, he has been the Director of the Blood Transfusion Center of EFS-Alsace in Strasbourg. He is a past president (1992-1995) and vice- president (2002-2010) of the Société Française de Transfusion Sanguine. He is member of several international medical societies, and author of more than 600 scientific publications.

Joachim Dupont – Director

Joachim Dupont graduated from Paris Dauphine University and began his career in risk management at Axa Corporate Solutions before joining Lazard Frère Gestion. In 2012, he co-founded Anaxago, an investment company and is now an administrator of more than 20 young innovative companies. ANAXAGO has become in few years the market leader in equity crowdfunding by offering a new form of investment and an alternative financing for innovative companies and real estate professionals. Anaxago has financed more than one hundred companies for more than € 50 million since 2012 thanks to a community of 5000 private investors. Since 2014 the company has been approved as a Participating Investment Advisor.

Martine Jandrot-Perrus, MD, PhD – Director

Research Director (DR1) at Inserm (UMR_S1148 Inserm Paris-Diderot University) ; Thrombosis Scientific Consultant. Internationally recognized expert of thrombosis and entitled with an Hospital Research contract in translational research with the AP-HP ; Martine Jandrot-Perrus is the author of 102 papers in international scientific journals and of 4 patents.

Christophe Pasik, MD – Director

Christophe is the co Founder (in 2006) and current CEO of Keocyt SAS a French pharmaceutical company. He is an active Business Angel, co founder of several healthcare societies and Board member of French Biotech and Healthcare companies. Prior to that and since 1990, he held various positions in Pharma companies such as Pfizer, Pharmacia, Catalent and Merck Lipha in France and abroad.







Understanding stroke

A new target — GPVI

GPVI is an attractive target to develop new and safe antithrombotic with the following advantages:

High efficacy

  • pivotal role in atherothrombosis
  • inhibition of thrombus growth
  • inhibition of leucocyte recruitment
  • inhibition of platelet procoagulant activity

Safety

  • preservation of physiological haemostasis
  • minor risk of bleeding

High specificity

  • no expected side effect

GPVI is a platelet membrane protein which belongs to the immunoglobulin superfamily and that is expressed exclusively by platelets and their precursor, the megacaryocytes.

GPVI is the receptor responsible for platelet activation by collagen and polymerized fibrin and as thus, it is involved in the initiation of thrombus formation.

GPVI contributes to the growth of the thrombus in two ways. First GPVI mediates platelet procoagulant activity via an initial adhesion to collagen followed by an activation leading to platelet secretion, recruitment of additional platelets and aggregation. Second GPVI behaves as a receptor for polymerized fibrin which lead to an amplification of thrombin generation and recruitment of circulating platelets.

Acticor Biotech new target GPVI in 3D
3D structure of GPVI

A striking result was to discover that GPVI deficiencies do not provoke bleeding while it contributes to protect mice from thrombosis in different models. Furthermore, the founders were the first to identify a patient with a genetic deficiency in GPVI who do not presents any bleeding disorder.

Several model of thrombosis have been evaluated with the murine antibody 9O12 which was the prototype of the humanized drug candidate ACT017. In these models, 9O12 was able to decrease the process of thrombosis in vivo or to protect animals in a lethal model.

Furthermore, elevated plasma levels of soluble GPVI in patients with stroke suggest that GPVI is activated and processed in these patients.







Credits

Images and illustrations

  • Header illustrations: © Getty Images, © Shutterstock © Fotolia
  • Paris 18e Hôpital Bichat by Henry Salomé, CC BY-SA 2.5-2.0-1.0, via Wikimedia Commons
  • Agoranov picture, © Agoranov, via http://www.agoranov.com
  • Catalent’s Kansas City, MO facility, © Catalent
  • Mediolanum’s building © Mediolanum Farmaceutici S.p.a.






Homepage

Nothing to display, yet.







Legal Mentions

Site Editor

Acticor Biotech SAS
Address :
46, rue Henri Huchard
75018 PARIS
FRANCE
Email: contact@acticor-biotech.com
SIREN: 798 483 285 RCS Paris
Publishing Director: Gilles AVENARD, CEO

Hosting

Hosting is provided by Tano Interactive SAS
Address: 1, rue Alfred Laurant, 92100 Boulogne-Billancourt, FRANCE
hosting@tano-interactive.com

No warranty and no liability

WhileActicor Biotech SAS is making great efforts to include accurate and up-to-date information, we make no representations or warranties, express or implied, as to the accuracy or completeness of the information provided on this Website and disclaim any liability for the use of this site or any site linked to it. Acticor Biotech SAS may change this site at any time without notice but does not assume any responsibility to update it. All users agree that all access and use of this Website and on any Website linked to from this site and the content thereof is at their own risk. Neither Acticor Biotech SAS nor any other party involved in creating, producing or delivering this Website or on any Website linked to from this site shall be liable in any manner whatsoever for any direct, incidental, consequential, indirect or punitive damages arising out of your access, use or inability to use this Website or any Website linked to from this site, or any errors or omissions in the content thereof.

Forward-looking information

This page may contain forward-looking information. Such information is subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented.

Links

Links to third party pages are provided for convenience only. We do not express any opinion on the content of any third party pages and expressly disclaim any liability for all third party information and the use of it.

Trademarks

All mentioned trademarks are owned by or licensed to Acticor Biotech SAS.

Copyright

The Website of Acticor Biotech SAS and the information contained and referenced therein are for informational purposes only. Any reproduction, retransmission or other use is strictly prohibited. Request for permission to reproduce any information contained on this Website should be addressed to Acticor Biotech SAS.







Understanding stroke

Stroke treatment

Current treatment lacks efficiency

Only one pharmaceutical treatment is presently approved by FDA and EMA for ischemic stroke: thrombolysis, which aims at dissolving the blood clot. This emergency treatment is being administered to approximately 15% of patients overall, mainly because it must be done within 4 hours and 30 minutes (as approved in EU, 3 hours in USA) of the onset of stroke symptoms, in a specialized neurovascular hospital unit.

Moreover, because this treatment could induce bleedings in some patients, it is subjected to some contraindications. Finally, its efficacy remains limited to an estimated 30% success rate. A meta-analysis from 5 randomised trials has shown that thrombolysis protects only around 13% of the patients treated.

Therefore a major need for a new stroke treatment capable of effectively treating a majority of ischemic stroke patients remains.

Since 2015, mechanical thrombectomy has been recognized in several clinical trials and has demonstrated efficacy based on clinical scores at 90 days. The method is based on the use of a device delivered by endovascular access proximal to the occlusion site to disrupt the clot. Although thrombectomy becomes a gold standard, the amount of patients treated remains limited.

Antiplatelet drugs (which inhibit blood platelets aggregation) proved their efficacy in ischemic diseases like myocardial infarction, but they are not recommended in the first 12 to 24 hours for stroke because they tend to induce bleedings that have catastrophic consequences in the brain.

Our innovative solution

In this context, Acticor Biotech took on the mission to develop an innovative antithrombotic compound which could be used in the first 12 hours before switching to antiplatelet agents. Considering the properties of the target GPVI our goal is to achieve an effective action against the formation and growth of the blood clot responsible for the ischemia, without increasing bleeding risks.







Understanding stroke

Stroke outcomes

The first cause of adult acquired disabilities

Despite sustained efforts worldwide to reduce cardiovascular diseases incidence and morbi-mortality, stroke or cerebral infarction remains the first cause of adult acquired disabilities and the third cause of death in industrialized countries. There is presently no effective treatment that can be safely used on most patients.

Each year, around one million patients in Europe experience a stroke and approximately 800,000 in the USA (one every 40 seconds). Worldwide, it is 15 million people who suffer stroke each year, and of these, 6 million die.

Stroke is a cardiovascular disease and is positively impacted by cardiovascular risk prevention. However the aging of the population largely compensates this and the number of stroke occurrence is still increasing in some age groups possibly due to changes of living habits.

Stroke outcomes are disastrous

  • Death: stroke is the 3rd cause of death in wealthy countries.
  • Handicaps: stroke is the first cause of serious long-term disability and the first cause of adult acquired handicap globally, and notably the 2nd cause of dementia after Alzheimer disease.

A major economic impact

In addition to being a major public health issue, stroke has a major economic impact. For instance in 2010 stroke-related medical costs and disability cost about 34 billion dollars to the USA. In the EU countries, the total annual cost of stroke is estimated at 38 billion euros, including the value of informal care. An international comparison of stroke cost studies showed that, on average, 0.27% of gross domestic product was spent on stroke by national health systems, and stroke care accounted for ∼3% of total health care expenditures.

Annually, 15 million first-ever strokes occur in the world, causing a total of 6 million deaths.







Understanding stroke

Stroke in brief

A large spectrum of symptoms

Stroke or cerebral infarction is a sudden neurological deficit caused by an infarction (80% cases) or a hemorrhage (20% cases) in the brain. It is characterized by a quick onset (instantaneous or within minutes) and is most of the time affecting one half of the body: hemiplegia, unilateral blindness but also speech impairment.

This large spectrum of symptoms varies from patient to patient but also depending on the hemorrhagic or ischemic origin of the stroke and the location of the neurological damage. However, in all cases, the sudden onset of a deformed mouth, a weakening of one side of the body (arm or leg) and/or difficulties to speak are the indication of a neurological problem that should be considered a potentially life-threatening medical emergency.

After onset, symptoms can disappear spontaneously within seconds or hours. In this case the event is referred to as Transient Ischemic Attack (TIA). Even if no neurological trouble sustains, this is a diagnostic and therapeutic emergency. All patients experiencing this type of symptoms must visit a doctor or the closest emergency service available.

Around 30% of strokes occur after this kind of transient symptoms, which are too often neglected by patients.

It usually takes a long time for survivors to recover spontaneously, from several weeks to several months, followed by a slower recovery phase that lasts for years.

The two types of stroke

Approximately 80% of strokes are the ischemic type. They are caused by the occlusion of an artery delivering blood to the brain (brain arteries but also carotids and vertebral arteries). When this happens, a part of the brain is deprived of oxygen and nutrients. This deprivation results in a cerebral infarction, which provokes neurological damages that result in severe disabilities or death if it lasts more than several minutes or hours.

The remaining 20% of strokes are hemorrhagic, subsequent to the rupture of a cerebral artery wall.

The probability of experiencing an ischemic stroke increases with age whereas hemorrhagic strokes occurrence is age independent. However, even if the mean age for stroke is 73 years (in Europe), 25% of strokes occur in patients below 65. Stroke can occur at all age, including childhood.







Our product — ACT017

Pipeline

acticorbiotech-pipeline3x-100

ACT017

In recent decades molecular engineering methods have seen impressive advances enabling the design of therapeutic antibodies and derivatives that now represent the fastest growing class of biopharmaceuticals .

Acticor Biotech product, ACT017, is a high affinity humanized  antibody fragment (Fab) directed against a new therapeutic target of major interest: the platelet glycoprotein VI (GPVI). ACT017 is produced in CHO cells using the GPEx technology (Catalent).

GPVI ACT17 Blockade of GPBI binding sites
ACT17 (Acticor Biotech): monoclonal Fab

ACT017 activity has been demonstrated in transgenic mice expressing the human GPVI and in primates. The results shown an inhibition of the collagen-induced platelet aggregation with no influence on bleeding time nor platelet count. The treatment will be a new option in the therapeutic landscape of stroke: it should be suitable for use in all patients, including those eligible to thrombolysis or not and patients beneficing of mechanical thrombectomy.







Understanding stroke

Nothing to display, yet.







Contact Us

Contact information

map-markerHeadquarter

Acticor Biotech SAS
Hôpital Bichat – INSERM U1148
46, rue Henri Huchard
75018 PARIS
France
Email: contact@acticor-biotech.com

map-markerOffices

Acticor Biotech SAS
8 rue des Saussaies
75008 PARIS
France
+33 (0)1 40 98 07 75

Contact form

Your Name (required)

Your Email (required)

Your Message (required)







Partners & Investors

acticor-biotech-partners-investors







About Us

Management Team

Gilles Avenard, MD – CEO

gilles_avenard-carre_300px-180x180-1Board member or advisor for several biotech companies ; co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. Gilles Avenard was involved in the development of several innovative medicines until their registration in Europe and the USA. Before that, he was Projects Director for Hoechst Marion Roussel (Sanofi) and Medical Director of Bio-Transfusion (LFB).

Olivier Favre Bulle, PhD – COO

cb-7045net_cropped-180x180Founder of 3Biotech, specialized in Pharmaceutical Development of Large and Small molecules. Site manager and European Head of Drug Development for Covance, Olivier also was head of NNE Pharmaplan France, a subsidiary of Novo Nordisk. He started at Rhône-Poulenc as Project Manager in Biological Drugs development. Chemical Engineer by training with a Ph.D in Bioengineering.

Eric Cohen, MBA – Finance Advisor

ericCEO and Founder of Agile Capital Markets; Advisor of several biotech & medtech companies; Investor Relations for Cellnovo Group. Eric was CFO of Mauna Kea Technologies (Euronext®: MKEA), Hybrigenics (Euronext®: ALHYG) and Teva Pharmaceuticals France (NASDAQ®: TLV) . He lead 2 IPO on Euronext® and several private and public financing round. He was also Head of Hybrigenics Business Services and Head of Operations (R&D and Production) at Mauna Kea.







Home

Nothing to display, yet.







About Us

Company Overview

Acticor Biotech Summary

Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.

Acticor Biotech is a spin-off company from Inserm (French National Institute of Health and Medical Research) founded in November 2013 and located in the Inserm U1148 building inside the Bichat Hospital in Paris.

Acticor Biotech develops a biologic drug candidate based on academic research on a platelet glycoprotein called GPVI. GPVI is a platelet receptor of collagen and polymerized fibrin.The drug candidate ACT017 is a humanized fragment of monoclonal antibody which binds to GPVI and inhibits platelet adhesion and aggregation on collagen and polymerized fibrin.  The efficacy and innocuity of ACT017 have been demonstrated in in vitro and in vivo animal models. Acticor Biotech is presently closing the drug discovery phase of the development by optimizing the compound for industrial production. The preclinical phase will start in early Q1-2017 and the goal is to start clinical trials in human Q1-2018.

Partners and awards

Concours Mondial de l’Innovation 2016

Laureate 2016, “Silver Economy” category

logo-innovation-2030

Tremplin des Entreprises 2016

Laureate 2016

Acticor Biotech, lauréate du Tremplin des Entreprises 2016

Since 2015, this project received the label EIP by Medicen (Innovative Enterprise) and has been recognized by Genopole. In 2016, Acticor Biotech was laureate of the Concours Mondial d Innovation (World Innovation Contest) and was also laureate of the Concours Tremplin dEntreprises du Sénat (national contest for innovative enterprises).

logoinserm

Recently, Acticor Biotech signed a partnership contract with INSERM and received grants from Bpifrance (innovation support).







About Us

Nothing to display, yet.